[1] Wang L, Zhou K, Wu Q, et al. Microanatomy of the metabolic associated fatty liver disease (MAFLD) by single-cell transcriptomics. J Drug Target, 2023,31(4):421-432. [2] Thomas M, Dighe M, Kolokythas O, et al. Ultrasound attenuation imaging vs MRI-PDFF, echogenicity and liver function for assessing degree of steatosis in NAFLD and non-NAFLD patients. Ultrasound Q,2023,39(4):188-193. [3] Qi R, Lu L, He T, et al. Comparing ultrasound-derived fat fraction and MRI-PDFF for quantifying hepatic steatosis: a real-world prospective study. Eur Radiol, 2025,35(5):2580-2588. [4] Wei C, Huang Y, Xi P, et al. The non-linear association between remnant cholesterol/high-density lipoproteincholesterol ratio and diabetic retinopathy: a cross-sectional study in type 2 diabetic patients. Diabetol Metab Syndr,2025,17(1):172. [5] Pan L, Jiang W, Liao L, et al. Association between the remnant cholesterol to high-density lipoprotein cholesterol ratio and the risk of coronary artery disease. Coron Artery Dis,2024,35(2):114-121. [6] 中国研究型医院学会肝病专业委员会,中国医师协会脂肪性肝病专家委员会,中华医学会肝病学分会脂肪肝与酒精性肝病学组,等.中国脂肪性肝病诊疗规范化的专家建议(2019年修订版).中华肝脏病杂志,2019,27(10):748-753. [7] Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology, 2005,41(6):1313-1321. [8] 熊印祥,宦丽君,刘巧.代谢相关脂肪性肝病患者SLCO1B1和APOE基因多态性与脂代谢紊乱关系研究.实用肝脏病杂志,2023,26(2):206-209. [9] 叶茜,郑东,杨昕宇,等.超声衰减参数联合血清PAI-1和ALT水平评估代谢相关脂肪性肝病患者肝脂肪变性程度的价值分析.实用肝脏病杂志,2024,27(1):44-47. [10] Wolf L, Jesper D, Vetter M,et al.Ultrasound derived fat fraction for non-invasive assessment of hepatic steatosis using liver histology as reference.Ultraschall Medizin,2023,44(15):206-209. [11] Nakamura Y, Hirooka M, Koizumi Y, et al. Diagnostic accuracy of ultrasound-derived fat fraction for the detection and quantification of hepatic steatosis in patients with liver biopsy. J Med Ultrason, 2025,52(1):85-94. [12] Huang H, Guo Y, Liu Z, et al. Remnant cholesterol predicts long-term mortality of patients with metabolic dysfunction-associated fatty liver disease. J Clin Endocrinol Metab,2022,107(8):e3295-e3303. [13] Yan L, Fu J, Juan NJ, et al. Ultrasound-derived fat fraction: a novel approach for assessing Wilson's disease-related hepatic steatosis. BMC Gastroenterol, 2025,25(1):465. [14] 韩煜东,张杰,章文瑾,等.超声来源的脂肪分数诊断代谢相关脂肪性肝病应用研究.实用肝脏病杂志,2025,28(4):553-556. [15] Ma X, Jia J, Cui H, et al. Association between the triglyceride to high density lipoprotein cholesterol ratio and the incidence of metabolic dysfunction-associated fatty liver disease: a retrospectivecohort study. BMC Gastroenterol,2024,24(1):389. [16] Tan Y, Chen S, Huang Z, et al. Impact of remnant cholesterol to high-density lipoprotein cholesterol ratio on risk of incident ASCVD: the Kailuan prospective cohort study. Nutr Metab (Lond),2025,22(1):51. [17] QiR, Lu L, He T, et al. Comparing ultrasound-derived fat fraction and MRI-PDFF for quantifying hepatic steatosis: a real-world prospective study. Eur Radiol,2025,35(5):2580-2588. [18] Xuan Y, Hu W, Wang Y, et al. Association between RC/HDL-C ratio and risk of non-alcoholic fatty liver disease in the United States. Front Med (Lausanne), 2024,29(11):142. [19] You T, Zhang S, Cheng S, et al. Consistency and reliability of ultrasound-derived fat fraction in hepatic steatosis assessment: influence of posture and breathing variations. BMC Med Imaging,2025,25(1):340. [20] Verdan S, Torri GB, Marcos VN, et al. Ultrasound-derived fat fraction for diagnosing hepatic steatosis: a systematic review and meta-analysis. Eur Radiol,2025,35(11):7421-7430. |